BRAF mutational status had a higher risk for shorter OS, albeit nonsignificant, in multivariable analysis (HR1.61 (95% C.I. 0.94–2.77); p = 0.086), with an unadjusted median OS of 11.5 months (95% C.I. 8.7–17.9; n = 59) in patients receiving first-line systemic treatment with a BRAF-mutant tumour versus 19.6 months (95% C.I. 14.6–22.7; n = 63) in patients with a BRAF-wildtype tumour. Here, BRAF is linked to neoplasm.